1.High Levels of Serum DPP-4 Activity Are Associated with Low Bone Mineral Density in Obese Postmenopausal Women.
Endocrinology and Metabolism 2016;31(1):93-99
BACKGROUND: Dipeptidyl peptidase 4/CD26 (DPP-4) is a widely expressed cell surface serine protease. DPP-4 inhibitors, one of common anti-diabetic agents play a protective role in bone metabolism in recent studies. A soluble form of DPP-4 is found in serum, and exhibits DPP-4 enzymatic activity. However, the physiological role of serum or soluble DPP-4 and its relationship with DPP-4 enzymatic function remain poorly understood. The aims of current study were to determine the association between serum DPP-4 activity and bone mineral density (BMD) in postmenopausal women. METHODS: We recruited data and serum samples from 124 consecutive healthy postmenopausal women aged >50 years. We divided study subjects into obese (body mass index [BMI] ≥25 kg/m2) and non-obese (BMI <25 kg/m2) postmenopausal women and examined the correlation between serum DPP-4 activity and clinical variables in each groups. RESULTS: A total of 124 postmenopausal women was enrolled, with a mean age of 59.9±7.1 years. The mean BMI of the study patients was 24.4±2.8 kg/m2. Regarding bone turnover markers, serum DPP-4 activity was positively correlated with serum calcium concentrations, intact parathyroid hormone, and serum C-telopeptide levels in all of the study subjects. However, there was no association between serum DPP-4 activity and BMD in the spine or femoral neck in all of the study subjects. Serum DPP-4 activity was negatively correlated (R=−0.288, P=0.038) with BMD of the spine in obese postmenopausal women. CONCLUSION: This study demonstrated for the first time that serum soluble DPP-4 activity was negatively correlated with BMD in obese postmenopausal women.
Biological Markers
;
Bone Density*
;
Calcium
;
Dipeptidyl Peptidase 4
;
Female
;
Femur Neck
;
Humans
;
Metabolism
;
Parathyroid Hormone
;
Postmenopause
;
Serine Proteases
;
Spine
2.Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation.
Sun Woo LIM ; Ji Zhe JIN ; Long JIN ; Jian JIN ; Can LI
The Korean Journal of Internal Medicine 2015;30(6):759-770
Despite strict pre- and post-transplantation screening, the incidence of new-onset diabetes after transplantation (NODAT) remains as high as 60%. This complication affects the risk of cardiovascular events and patient and graft survival rates. Thus, reducing the impact of NODAT could improve overall transplant success. The pathogenesis of NODAT is multifactorial, and both modifiable and nonmodifiable risk factors have been implicated. Monitoring and controlling the blood glucose profile, implementing multidisciplinary care, performing lifestyle modifications, using a modified immunosuppressive regimen, administering anti-metabolite agents, and taking a conventional antidiabetic approach may diminish the incidence of NODAT. In addition to these preventive strategies, inhibition of dipeptidyl peptidase-4 (DPP4) by the gliptin family of drugs has recently gained considerable interest as therapy for type 2 diabetes mellitus and NODAT. This review focuses on the role of DPP4 inhibitors and discusses recent literature regarding management of NODAT.
Animals
;
Blood Glucose/drug effects/metabolism
;
Diabetes Mellitus/diagnosis/*drug therapy/enzymology/etiology
;
Dipeptidyl Peptidase 4/*metabolism
;
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
;
Humans
;
Organ Transplantation/*adverse effects
;
Risk Assessment
;
Risk Factors
;
Treatment Outcome
3.Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation.
The Korean Journal of Internal Medicine 2013;28(6):639-645
Dipeptidylpeptidase (DPP) 4, also known as CD26, is an enzyme present on the surface of a number of different cell types. It is also found within cells and as a soluble protein in body fluids. It can specifically truncate proteins at the penultimate N-terminus residue for some amino acids, such as alanine, proline, serine, and perhaps others. DPP4 has been implicated in regulating the in vitro and in vivo functional activities of a number of hematopoietically active molecules, and this information, along with that on inhibition of DPP4, has been studied in efforts to enhance hematopoietic cell transplantation (HCT), hematopoiesis after stress in mouse models, and in the clinical setting of single-unit cord blood (CB) HCT. This article reviews the current status of this compound's effects on regulatory proteins, the field of CB HCT, a potential role for modulating DPP4 activity in enhancing single-unit CB HCT in adults, and future aspects in context of other cellular therapies and the area of regenerative medicine.
Animals
;
*Cord Blood Stem Cell Transplantation
;
Dipeptidyl Peptidase 4/*metabolism
;
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
;
Hematopoiesis/*drug effects
;
Hematopoietic Stem Cells/*drug effects/enzymology
;
Humans
;
Regenerative Medicine/*methods
;
Signal Transduction/drug effects
4.Design, synthesis and in vitro activity of glycinamide-bearing compounds as DPP-IV inhibitors.
Bei HAN ; Yi HUAN ; Zi-Yun LIN ; Peng LI ; Zhu-Fang SHEN ; Da-Li YIN ; Hai-Hong HUANG
Acta Pharmaceutica Sinica 2010;45(11):1379-1384
To research the structure-activity relationship (SAR) of glycinamide-bearing compounds that used as inhibitors of dipeptidyl peptidase IV (DPP-IV), P32/98 and compound A were chosen as the leading compounds, heterocycles containing nitrogen atom were introduced to form amide, and different residues on a-position of carbonyl were designed. The nineteen designed compounds were synthesized by a simple route and were evaluated as inhibitors of DPP-IV. All of the structures were characterized by 1H NMR and HRMS. The preliminary SAR result was obtained.
Dipeptidyl Peptidase 4
;
metabolism
;
Dipeptidyl-Peptidase IV Inhibitors
;
chemical synthesis
;
chemistry
;
pharmacology
;
Drug Design
;
Glycine
;
analogs & derivatives
;
chemistry
;
Magnetic Resonance Spectroscopy
;
methods
;
Molecular Structure
;
Piperazines
;
chemistry
;
pharmacology
;
Structure-Activity Relationship
5.Functional defect of partial homing receptor on human cord blood hematopoietic stem/progenitor cells.
Xu-Han ZHANG ; Zi-Min SUN ; Hui-Lan LIU ; Xing-Bing WANG ; Liang-Quan GENG
Journal of Experimental Hematology 2010;18(2):445-449
This study was aimed to investigate the function defect of partial homing receptor on cord blood hematopoietic stem cells (CBHSC) and explore efficacy and feasibility of intervention in vitro. The expression and activity of active groups in P, E-selectin ligands on CD34+ cells from cord blood, bone marrow and peripheral blood were detected by flow cytometry; meanwhile the expression of active groups in selectin ligands on CD34+ cells treated by fucosyl transferase in vitro was determined by flow cytometry. The results indicated that the expression levels of CD26 on the surface of stem/progenitor cells (CD34+) from cord blood, bone marrow and peripheral blood were (7.62+/-0.63)%, (6.35+/-0.89)% and (6.18+/-0.91)% (p>0.05) respectively. And the activities of CD26 of the three sources of stem cells were 67.15 U/1000 cells (1 U=1 pmol/min), 26.85 U/1000 cells and 20.95 U/1000 cells respectively, in which the activity of CD26 on surface of CD34+ from cord blood was significantly higher than that from other both sources (p<0.01). The expression levels of P-selectin ligand on the stem/progenitor cells three kinds were (83.46+/-6.33)%, (15.65+/-0.89)% and (80.17+/-6.85)%, and the expression levels of E-selectin ligand on stem/progenitor cells of three kinds were (25.31+/-1.03)%, (26.34+/-0.89)% and (29.79+/-1.78)% respectively. The expression of E-selectin ligand on the surface of cord blood stem/progenitor cell CD34+ increased from (25.31+/-1.03)% to (63.23+/-1.08)% after glycosylation engineering. It is concluded that there is no significant difference of the expression of CD26 between the three sources of stem/progenitor cells, but the activity of CD26 in cord blood was obviously higher than that in bone marrow and peripheral blood. The expression of P-selectin ligand on bone marrow stem/progenitor cell was lower than that on stem cells of cord blood and peripheral blood. Glycosylation engineering can promote and elevate the expression of E-selectin ligand on the surface of CD34+ cells from cord blood.
Antigens, CD34
;
metabolism
;
Bone Marrow Cells
;
cytology
;
metabolism
;
Cells, Cultured
;
Dipeptidyl Peptidase 4
;
metabolism
;
Fetal Blood
;
cytology
;
Hematopoietic Stem Cells
;
cytology
;
metabolism
;
Humans
;
Receptors, Fibroblast Growth Factor
;
metabolism
;
Sialoglycoproteins
;
metabolism
;
Stem Cells
;
cytology
;
metabolism
6.Development of peptidic MERS-CoV entry inhibitors.
Shuai XIA ; Qian WANG ; Shu-wen LIU ; Lu LU ; Shi-bo JIANG
Acta Pharmaceutica Sinica 2015;50(12):1513-1519
In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.
Antiviral Agents
;
pharmacology
;
Coronavirus Infections
;
drug therapy
;
Dipeptidyl Peptidase 4
;
metabolism
;
Drug Design
;
Humans
;
Middle East Respiratory Syndrome Coronavirus
;
drug effects
;
physiology
;
Peptides
;
pharmacology
;
Spike Glycoprotein, Coronavirus
;
metabolism
;
Virus Internalization
;
drug effects
7.Clinical and Biological Character in Mouse Models for Middle East Respiratory Syndrome Generated by Transduction with Different Doses of DPP4 Molecule.
Yanfeng YAO ; Jiaming LAN ; Fengdi LI ; Peihua NIU ; Pin YU ; Lu SHUAI ; Linlin BAO ; Wenjie TAN ; Chuan QIN
Chinese Journal of Virology 2015;31(6):593-600
In this study, we evaluated the difference ot biological characteristics in the MERS-CoV infected mice model in prior to transduction with different dosage of human DPP4. Firstly, we transduced different dosage of DPP4 (high or low) into mice, and then challenged them with MERS-CoV in order to establish the model. After establishment of mice model, we observed the clinical signs of disease, virus replication, immunopathogenesis and antibody response. The results indicated that the infected mice showed typical pneumonia, virus replication, histological lesions, and neutralizing antibody production. Moreover, the high dosage group was superior to the low dosage group. Fourteen days after infection, the specific antibody to virus structural protein and neutralizing antibody were analyzed, the high dosage group induced higher level antibody. In summary, the MERS-CoV infected mice model were established prior transduction with DPP4, and the level of DPP4 influenced the clinical signs of disease, virus replication and antibody response in this model.
Animals
;
Coronavirus Infections
;
enzymology
;
genetics
;
pathology
;
virology
;
Dipeptidyl Peptidase 4
;
genetics
;
metabolism
;
Disease Models, Animal
;
Female
;
Humans
;
Mice
;
Mice, Inbred BALB C
;
Middle East Respiratory Syndrome Coronavirus
;
genetics
;
physiology
8.Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
Young Min CHO ; Rhonda D WIDEMAN ; Timothy J KIEFFER
Endocrinology and Metabolism 2013;28(4):262-274
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which contributes to decreased postprandial glycemic excursions. In the 1990s, chronic subcutaneous infusion of GLP-1 was found to lower blood glucose levels in patients with type 2 diabetes. However, GLP-1's very short half-life, arising from cleavage by the enzyme dipeptidyl peptidase 4 (DPP-4) and glomerular filtration by the kidneys, presented challenges for clinical use. Hence, DPP-4 inhibitors were developed, as well as several GLP-1 analogs engineered to circumvent DPP-4-mediated breakdown and/or rapid renal elimination. Three categories of GLP-1 analogs, are being developed and/or are in clinical use: short-acting, long-acting, and prolonged-acting GLP-1 analogs. Each class has different plasma half-lives, molecular size, and homology to native GLP-1, and consequently different characteristic effects on glucose metabolism. In this article, we review current clinical data derived from each class of GLP-1 analogs, and consider the clinical effects reported for each category in recent head to head comparison studies. Given the relatively brief clinical history of these compounds, we also highlight several important efficacy and safety issues which will require further investigation.
Blood Glucose
;
Diabetes Mellitus, Type 2*
;
Dipeptidyl Peptidase 4
;
Filtration
;
Gastric Emptying
;
Glucagon
;
Glucagon-Like Peptide 1*
;
Glucose
;
Half-Life
;
Head
;
Humans
;
Infusions, Subcutaneous
;
Insulin
;
Kidney
;
Metabolism
;
Peptides
;
Plasma
;
Venoms
;
Liraglutide
9.Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
Young Min CHO ; Rhonda D WIDEMAN ; Timothy J KIEFFER
Endocrinology and Metabolism 2013;28(4):262-274
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which contributes to decreased postprandial glycemic excursions. In the 1990s, chronic subcutaneous infusion of GLP-1 was found to lower blood glucose levels in patients with type 2 diabetes. However, GLP-1's very short half-life, arising from cleavage by the enzyme dipeptidyl peptidase 4 (DPP-4) and glomerular filtration by the kidneys, presented challenges for clinical use. Hence, DPP-4 inhibitors were developed, as well as several GLP-1 analogs engineered to circumvent DPP-4-mediated breakdown and/or rapid renal elimination. Three categories of GLP-1 analogs, are being developed and/or are in clinical use: short-acting, long-acting, and prolonged-acting GLP-1 analogs. Each class has different plasma half-lives, molecular size, and homology to native GLP-1, and consequently different characteristic effects on glucose metabolism. In this article, we review current clinical data derived from each class of GLP-1 analogs, and consider the clinical effects reported for each category in recent head to head comparison studies. Given the relatively brief clinical history of these compounds, we also highlight several important efficacy and safety issues which will require further investigation.
Blood Glucose
;
Diabetes Mellitus, Type 2*
;
Dipeptidyl Peptidase 4
;
Filtration
;
Gastric Emptying
;
Glucagon
;
Glucagon-Like Peptide 1*
;
Glucose
;
Half-Life
;
Head
;
Humans
;
Infusions, Subcutaneous
;
Insulin
;
Kidney
;
Metabolism
;
Peptides
;
Plasma
;
Venoms
;
Liraglutide
10.Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma.
Meng-zhen ZHANG ; Yu-huan QIAO ; Zhen-he SUO
Chinese Journal of Oncology 2008;30(11):848-852
OBJECTIVETo investigate the expression of dipeptidyl peptidase IV (DPPIV) in patients with epithelial ovarian carcinoma (EOC) and its clinical significance.
METHODSImmunohistochemistry (IHC) was used to detect the expression of DPPIV protein in 378 formalin-fixed paraffin-embedded EOC tissue samples. The expression of DPPIV mRNA in 86 EOC tissue samples were examined by in situ hybridization (ISH) using specific FITC-labelled RNA probes. Forty-two samples of normal ovarian tissues were used as control. Statistical analyses were carried out by Chi-square test, Spearman rank correlation and Kaplan-Meier method.
RESULTSAmong the 378 epithelial ovarian carcinomas, 351 (92.9%) showed a positive expression of DPPIV protein, while only 25/42 (59.5%) of normal ovaries had a positive expression by semi-quantitative IHC analysis. The expression level of DPPIV protein was significantly lower in the normal ovaries than that in ovarian carcinomas (chi(2) = 18.4, P = 0.001). There was no significant correlation between the expression of DPPIV protein and age, FIGO stage and histological grade (P > 0.05). However, the expression of DPPIV protein was significantly associated with histological type (chi(2) = 28.5, P = 0.005). The patients with high level expression of DPPIV protein likely had a poor prognosis in terms of overall survival (P = 0.02). Of the 86 patients, 84 (97.7%)showed positive expression of DPPIV mRNA, also higher than that in normal ovarian tissues (P < 0.05). A statistically significant correlation between DPPIV mRNA and protein expression was observed (r(s) = 0.66, P = 0.001).
CONCLUSIONDPPIV may be involved in the carcinogenesis of ovarian cancer, and may become a potential prognostic marker for epithelial ovarian carcinoma.
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor ; metabolism ; Carcinoma, Endometrioid ; metabolism ; pathology ; Cystadenocarcinoma, Mucinous ; metabolism ; pathology ; Cystadenocarcinoma, Serous ; metabolism ; pathology ; Dipeptidyl Peptidase 4 ; biosynthesis ; genetics ; Female ; Follow-Up Studies ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms ; metabolism ; pathology ; Prognosis ; RNA, Messenger ; metabolism ; Survival Rate